World Novel Drug Discovery Summit South Korea
Through increased government investment in AI and in silico technologies, and prominent partnerships and milestones from companies like 1st Biotherapeutics, Galux, Hanmi Pharm, and LG Research AI, Korea is rapidly emerging as a global hub for drug discovery innovation as biopharma seeks to create best-in-class platforms to be best positioned for global partnering and licensing opportunities.
The World Novel Drug Discovery Summit South Korea is Korea’s first and only industry-led conference designed to accelerate the creation of best-in-class potential platforms for next-generation modalities by leveraging AI and state-of-the-art drug discovery technologies for smarter, faster, and de-risked drug discovery.
View the full event guide here.
Providing you with the tools to innovate your drug discovery efforts across ADCs, induced proximity, peptides, and beyond, join 100+ drug discovery enthusiasts, from strategic decision-makers to hands-on technical experts, across Korean innovators, global pharma leaders, and industry-leading service providers, to discover how integrated drug discovery workflows can support your novel drug discovery from siloed innovation to fully connected, intelligent platforms.
If you work in drug discovery, this is where you need to be to generate new insights and connections that enable safer, faster, and seamless drug discovery.
Unmissable Event Highlights:
- Global Discovery Leaders Panel Discussion: Hear from Korean and international discovery leaders from Eli Lilly, Hanmi Pharm, and KIT on the state of play of AI/ML in drug discovery, areas of promise and bottlenecks, and strategies to foster global collaborations
- Industry-Leading Platform Showcases: Discover insights from leading discovery platform innovators like AIGENDRUG, Degron Tx, Portrai and ONCOCROSS, blending technical and strategic insights with experimental validation to unlock best-in-class discovery
- Next-Generation Modality Case Studies: Access modality-agnostic discovery insights with content split evenly across biologics and small molecules, including up- and coming modalities such as ADCs, induced proximity and molecular glues, peptides and vaccines
- AI/ML De Novo Discovery Workshop: Deep dive into AI/ML and in silico model training, applications, validation, limitations, and iterative DBTL workflows with AIGEN Sciences, Korea University, and Seoul National University
With content for multiple teams, you can take advantage of the group discounts of up to 20% available.
